Previous studies demonstrated that mTOR inhibitors may reduce the recurrence of HCC after LT (Grigg et al., 2019), although most of these studies compared an mTOR inhibitor plus a low dose of TAC and a regular dose of TAC only. Here, MTOR is linked to hepatocellular carcinoma.